Industry news

Popular Tags

industry life COVID-19 FDA science research Hi-Tech medical technology medindustriya business WHO Trump cancer law Alzheimer's disease Industry homeopathy Alzheimer medical brain medicine investment hepatitis c medical and health genome Alzheimer's multiple sclerosis human brain DNA digital biomarkers Nobel Prize medicine and health Parkinson’s disease diabetes hacker attack Amazon startup biology 3D printing biotechnology charity tecnolgy coronavirus cyber-security vaccine health

April 28, 2015, 10:17

In Fight Against Alzheimer's, $100 Million Genentech (RHHBY) Trial in Colombia May Be Ground Zero

COLOMBIA -- A $100 million Genentech (RHHBY) study on Alzheimer’s treatment is focusing on members of a Colombian family who may carry a rare gene that leads to early onset dementia by age 45, the Wall Street Journal reported this morning. If the trials pan out, it could lead to the development of a drug that could treat the cause of Alzheimer’s disease, rather than help manage symptoms.

Alzheimer's industry

Site Map